tbuckley/cabot-search huggingface dataset:
PWE-160 Exploring Gastrointestinal Symptoms and Their Impact on Quality Of Life in Patients With Neuroendocrine Tumours
Authors: M Williams, K Reid, J Lewis, A Christian, L Sunderraj, H Williams, A Rees, MS Khan
Journal: Gut (2016)

<h3>Introduction</h3> Treatments available to patients with neuroendocrine tumours(NETs) have been studied for their effect on tumour progression and carcinoid syndrome. However, there is minimal evidence on gastrointestinal (GI) symptom burden and its impact on quality of life (QoL). We aimed to determine whether patients with NETs receiving treatment experience GI symptoms, and to explore the impact that these symptoms have on QoL. <h3>Methods</h3> A prospective cohort of 46 patients with histologically confirmed NET visiting endocrine and oncology clinics completed GSRS (gastrointestinal symptom rating scale) and EORTC QLQ-GINET21 QoL questionnaires prior to establishment of a gastroenterology NET service. <h3>Results</h3> The majority of patients had a midgut(70%) or pancreatic(15%) primary with 96% having metastatic disease. Duration of diagnosis was 42 months (range 2–249), 91% having stable disease. The majority of patients reported GI symptoms including: abdominal cramps(80%), bloating(74%), excessive passing of wind(87%) and faecal urgency(87%). 50% had a stool frequency of more than 5 times a day and 71% of patients scored type 5 or higher on the Bristol Stool Chart. 54% of patients reported greasy/oily stool. 60% scored their QoL to be less than 7 out of 10. When asked how much bowel symptoms were affecting quality of life, 58% of patients scored more than 5 out of 10. 97% reported their illness to be distressing for those close to them. <h3>Conclusion</h3> This study represents the first systematic analysis of specifically defined GI symptoms experienced by NET patients. Despite having stable disease, many patients frequently experience GI symptoms which have a negative impact on QoL. <h3>Disclosure of Interest</h3> None Declared
SAT0293 Serum and Tear Cytokines and Chemokines Levels as Disease Activity Biomarkers in Patients with Primary Sjögren's Syndrome
Authors: A.A. Castillo Ortiz, R.E. Barbosa Cobos, L.T. Becerril Mendoza, G. Lugo Zamudio, V. Lima Gόmez, M.A. Moreno Eutimio, N.G. Nieto Velázquez, A.A. Tzec Pérez
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Evidence suggests that levels of different cytokines in primary Sjögren9s syndrome (pSS) are associated with cell infiltration degree within lacrimal and salivary glands and severity of the disease. Chemokines appear to contribute to the pathogenesis of pSS. <h3>Objectives</h3> To evaluate the association between serum and tear Th1/Th2/Th17 cytokines and chemokines leves and disease activity in patients with pSS. <h3>Methods</h3> Case-control study, 19 patients with pSS and 13 healthy controls were included. Disease activity was assessed by EULAR Sjögren9s Syndrome Disease Activity Index (ESSDAI); serum and tear IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10, IL-17, IP10, MCP-1, MIG, RANTES and IL-8 levels were measured by bead-based assays following the sandwich immunoassay principle (BD Cytometric Bead Array; BD Biosciences). Differences between groups were analyzed using the Mann-Whitney U test, correlation was estimated by Spearman9s correlation coefficient. <h3>Results</h3> TNF, IL-2, IL-4, IL-6, IL-10, IP-10, MCP-1, RANTES and IL-8 tear levels were statistically different between controls and patients with pSS (p&lt;0.005). Significant correlation (p&lt;0.005) was showed in patients between serum IL-6 and serum IL-2 (r=0.652), IL-4 (r=0.731); serum IL-2 and serum IP-10 (r=0.640); serum IL-2 and tear IL-2 (r=0.614), IL-8 (r=0.723), IP-10 (r=0.795), MIG (r=0.755); serum IL-4 and tear IL-8 (r=0.696), MIG (r=0.707); serum IP-10 and serum MIG (r=0.847), RANTES (r=0.626); serum IP-10 and tear IP-10 (r=0.619); serum MIG and serum RANTES (r=0.719); serum MIG and tear IL-17 (r=0.619); serum RANTES and tear IL-2 (r=0.628), IL-4 (r=0.619), IL-6 (r=0.736), IL-8 (r=0.770), IP-10 (r=0.687), MCP-1 (r=0.566), MIG (r=0.740). <h3>Conclusions</h3> Increased tear Th1/Th2 cytokines and chemokines levels were found in pSS. No correlation was found between serum or tear cytokines and chemokines levels and pSS disease activity. <h3>References</h3> Chen W, Cao H, Lin J, Olsen N, Zheng SG. Biomarkers for primary Sjögren syndrome. Genomics Proteomics Bioformatics 2015; 11:219–23 Coursey TG, de Paiva CS. Managing Sjögren9s Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy. Clin Ophthalmol. 2014; 8:1447–58. Tincani A, Andreoli L, Cavazzana I. Novel aspects of Sjögren9s Syndrome in 2012. Bio Med Central Medicine 2013;11:93 Lee SY, Han SJ, Nam SM, Yoon SC, Ahn JM, Kim TI et al. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients. Am J Ophthalmol 2013; 156:247–253 Kang MH, Kim MK, Lee HJ, Lee HI, Wee WR, Lee JH. Interleukin-17 in various ocular surface inflammatory diseases. J Korean Med Sci 2011; 26:938–44 <h3>Disclosure of Interest</h3> None declared
Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study
Authors: Ajai Chari, Saurabh Chhabra, Saad Usmani, Sarah Larson, Ruben Niesvizky, Jeffrey Matous, Cristina Gasparetto, Beata Holkova, Matthew Lunning, Jason Valent, Larry D. Anderson, Chatchada Karanes, Long Kwei, Lipo Chang, Thorsten Graef, Elizabeth Bilotti, Kevin McDonagh
Journal: Blood (2015)
The Sea Urchin sns5 Chromatin Insulator Improves the Likelihood of Lentiviral Vectors in Erythroid Milieu By Organizing an Independent Chromatin Domain at the Integration Site
Authors: Elena Baiamonte, Rosalia Di Stefano, Melania Lo Iacono, Barbara Spina, Angela Vitrano, Rosario Di Maggio, Massimiliano Sacco, Giovanni Spinelli, Aurelio Maggio, Santina Acuto, Vincenzo Cavalieri
Journal: Blood (2015)
SP0187 Why Missing Data Is A Problem, and What You shouldn't Do To Solve It
Authors: T. Frisell
Journal: Annals of the Rheumatic Diseases (2016)

Missing data, where either entire observations or individual variable values are for some reason not available for analysis, is a common challenge to research using complex data bases. Although missing data clearly lead to a loss of information and hence reduced statistical power, a more insidious consequence is that this lack of data may introduce selection bias, which could potentially invalidate the entire study. Fortunately, many solutions to this problem has been put forth, based on different ways of filling out (imputing) values where there are none. Unfortunately, several of these solutions are inherently flawed and may introduce more bias then they remove. This brief presentation will introduce central concepts in the literature on missing data, go through the circumstances when missing data may introduce selection bias, and show some flaws in several methods sometimes used to impute data. <h3>Disclosure of Interest</h3> None declared
Long-Term Follow-Up of Treatment for Acute Myeloid Leukemia with Allogeneic Hematopoetic Cell Transplantation Using BuCy2 as Preparation.
Authors: Shubham Pant, Pamela Ann Crilley, Anthony J. Dodds, Jeffrey Szer, Brian J. Bolwell, Patrick Elder, Michael Styler, Matt Kalaycio, Ronald Sobecks, Ian Nivison-Smith, Belinda R. Avalos, Edward A. Copelan
Journal: Blood (2006)
Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.
Authors: Ulrich Jaeger, Otto Krieger, Georg Hopfinger, Cathrin Skrabs, Christine Einberger, Veronika Huter, Hubert Hausmaninger, Johannes Drach, Markus Raderer, Michael Woo, Helen Melzer, Richard Greil, Michael A Fridrik
Journal: Blood (2008)
Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Authors: Mikkael A. Sekeres, Rami S. Komrokji, Jeffrey E. Lancet, Ramon V. Tiu, Anjali S. Advani, Manual Afable, Ricki Englehaupt, Joyce Juersivich, David Cuthbertson, Jennifer Paleveda, Ronald Paquette, April Smith, Lori Strozniak, Alan F. List, Jaroslaw P. Maciejewski
Journal: Blood (2011)
THU0122 Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis: Table 1
Authors: A. Deodhar, B. Bitman, Y. Yang, D. Collier
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) disease. <h3>Objectives</h3> To evaluate changes in metabolic and lipid CV risk factors in patients with RA treated with etanercept (ETN) <h3>Methods</h3> This was an exploratory analysis in a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ETN in patients with moderate RA despite disease-modifying antirheumatic drug therapy. Adults with active, moderate RA (3.2 &lt; DAS28-CRP ≤ 5.1) for ≥6 months and receiving a stable dose of methotrexate for ≥8 weeks were randomized 1:1 to receive ETN 50 mg or placebo (PBO) weekly for 12 weeks; after week 12, all patients received ETN 50 mg weekly for 12 weeks. Laboratory tests evaluated baseline, week-12, and week-24 levels of metabolic and lipid analytes, and shifts in grade (low, normal, or high). <h3>Results</h3> In total, 210 patients enrolled: 104 PBO and 106 ETN; 77% female, 86% white, and mean (SD) age 56 (12) years. There were 14% with a medical history of type 2 diabetes and 30% a medical history of hyperlipidemia or hypercholesterolemia; 22% were receiving statins, 10% oral antidiabetic medications, 3% insulin, and 52% prednisone. Baseline, week-12, and week-24 values for each analyte are listed below. Over 24 weeks, there were no significant changes in metabolic or lipid analytes. Patients with diabetes and hyperlipidemia resembled the overall study population, except for decreases in fasting glucose and insulin through week 12 and slight decreases in hemoglobin A1C through week 24 in diabetics receiving ETN (n=17). For the majority of patients, all analytes were in the normal range at baseline and remained normal at week 24.There were no gross abnormalities in liver function tests. Safety results are consistent with the current safety profile. <h3>Conclusions</h3> Treatment with ETN did not adversely affect the levels of traditional metabolic and lipid CV risk factors in patients with RA. Results in patients with diabetes are hypothesis generating and might be clinically relevant if demonstrated in a larger study. <h3>Disclosure of Interest</h3> A. Deodhar Grant/research support from: AbbVie, Amgen Inc., Boehringer Ingelheim, Janssen, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Amgen Inc., Boehringer Ingelheim, Janssen, Novartis, Pfizer, and UCB, B. Bitman Shareholder of: Amgen Inc., Employee of: Amgen Inc., Y. Yang Shareholder of: Amgen Inc., Employee of: Amgen Inc., D. Collier Shareholder of: Amgen Inc., Employee of: Amgen Inc.
Ibrutinib Sensitizes AML Cells to ROS Inducers Via a BTK-Independent Mechanism
Authors: Lianne E Rotin, Marcela Gronda, Neil Maclean, Feng-Hsu Lin, Jeff Wrana, Alessandro Datti, Dwayne L Barber, Michael F Moran, Mark D Minden, Malik Slassi, Aaron D Schimmer
Journal: Blood (2014)
Risk of Leukemia in Genetic Subgroups of Congenital Neutropenia (CN): Comparison of Patients with Mutations in HAX1 or ELA2
Authors: Cornelia Zeidler, Jean Donadieu, Gusal Pracht, Blandine Beaupain, Ludwig Hoy, Martin Zimmermann, Christine Bellanne-Chantelot, Christoph Klein, Manuela Germeshausen, Karl Welte
Journal: Blood (2008)
A Phase Ib/II Study of Combined Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
Authors: Januario E. Castro, Michael Y. Choi, Carlos I. Amaya-Chanaga, Natalie Nguyen, Colin MacCarthy, Thomas J. Kipps
Journal: Blood (2016)
Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease
Authors: Andrew E. Hendifar, Alberto M. Marchevsky, Richard Tuli
Journal: Journal of Thoracic Oncology (2016)

Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies that arise from neuroendocrine cells throughout the body, most commonly originating from the lungs and gastrointestinal tract. Lung NETs can be classified as well differentiated (low-grade typical carcinoids [TCs] and intermediate-grade atypical carcinoids [ACs]) and poorly differentiated (high-grade large cell neuroendocrine carcinoma or SCLC). The incidence of these tumors is increasing, but disease awareness remains low among thoracic specialists, who are often involved in the diagnosis and early treatment for these patients. An accurate and timely diagnosis can ensure the implementation of appropriate treatment and have a substantial impact on prognosis. However, lung NET classification and diagnosis, particularly for TCs/ACs, are complicated by several factors, including a variable natural history and nonspecific symptoms. Surgery remains the only curative option for TCs/ACs, but there is a lack of consensus between lung NET management guidelines regarding optimal treatment approaches in the unresectable/metastatic setting on account of the limited availability of high-level clinical evidence. As a result, a multidisciplinary approach to management of lung NETs is required to ensure a consistent and optimal level of care. RADIANT-4 is the first phase III trial involving a large subpopulation of patients with advanced well-differentiated lung NETs to report reductions in the risk for disease progression and death with everolimus over placebo. This led to the recent U.S. approval of everolimus-the first agent approved for advanced lung TCs/ACs. To further improve evidence-based care, additional randomized controlled trials in patients with lung carcinoids are needed.
Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor
Authors: Thuy Nguyen, Jun‐Xu Li, Brian F. Thomas, Jenny L. Wiley, Terry P. Kenakin, Yanan Zhang
Journal: Medicinal Research Reviews (2016)

The cannabinoid CB1 receptor is a G protein coupled receptor and plays an important role in many biological processes and physiological functions. A variety of CB1 receptor agonists and antagonists, including endocannabinoids, phytocannabinoids, and synthetic cannabinoids, have been discovered or developed over the past 20 years. In 2005, it was discovered that the CB1 receptor contains allosteric site(s) that can be recognized by small molecules or allosteric modulators. A number of CB1 receptor allosteric modulators, both positive and negative, have since been reported and importantly, they display pharmacological characteristics that are distinct from those of orthosteric agonists and antagonists. Given the psychoactive effects commonly associated with CB1 receptor agonists and antagonists/inverse agonists, allosteric modulation may offer an alternate approach to attain potential therapeutic benefits while avoiding inherent side effects of orthosteric ligands. This review details the complex pharmacological profiles of these allosteric modulators, their structure-activity relationships, and efforts in elucidating binding modes and mechanisms of actions of reported CB1 allosteric modulators. The ultimate development of CB1 receptor allosteric ligands could potentially lead to improved therapies for CB1-mediated neurological disorders.
Differential expression of SEPT9 splice variants in malignant ovarian tumors and during the cell cycle
Authors: Kyle Matchett, Katherine Borthwick, Jim Paul, Robert Brown, Peter Hall, S.E. Russell
Journal: Cancer Research (2008)

4244  A common feature of the septin family of genes is alternative splicing with generation of multiple transcripts. In SEPT9, up to 18 such transcripts have been identified by various combinations of 5’ and 3’ ends. With respect to the 5’ transcripts, we have previously reported that two of these, SEPT9_v1 and v4* are upregulated in sporadic ovarian tumors. Our current studies are focused on determining the significance of this observation. Initially, we sought to determine if these changes are clinically relevant. We therefore analyzed SEPT9 expression in a bank of ovarian tumors for which outcome and various clinical parameters were known. RNA was extracted from 100 FFPE ovarian tumor sections from women enrolled in the Scottish Randomised Trial in Ovarian Cancer (SCOTROC), which compares paclitaxel-carboplatin and docetaxel-carboplatin chemotherapy regimes. Primers were optimized to amplify each 5’ SEPT9 transcript by qRT-PCR in each sample and the profile analyzed for correlations with clinical data. In agreement with previous data, we observed elevated expression of SEPT9_v1 and v4* in SCOTROC tissues compared to normal ovarian tissue (p
Endothelial Progenitor Cells Are the Bone Marrow Cell Population in Mice with Monocrotaline-Induced Pulmonary Hypertension Which Induce Pulmonary Hypertension in Healthy Mice
Authors: Jason M. Aliotta, Mandy Pereira, Mark Dooner, Michael DelTatto, Elaine Papa, Sicheng Wen, Laura R. Goldberg, Peter J. Quesenberry
Journal: Blood (2015)
Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial
Authors: Michel Baulac, Felix Rosenow, Manuel Toledo, Kiyohito Terada, Ting Li, Marc De Backer, Konrad J Werhahn, Melissa Brock
Journal: The Lancet Neurology (2016)
Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition
Authors: Giulia Perrone, Teru Hideshima, Hiroshi Ikeda, Yutaka Okawa, Diana Cristea, Loredana Santo, Gullu Gorgun, Elisabetta Calabrese, Noopur Raje, Michele Baccarani, Michele Cavo, Kenneth C. Anderson
Journal: Blood (2008)
LP07 : Simeprevir (SMV) plus daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: Interim results from the phase II impact study
Authors: E. Lawitz, F. Poordad, J. Gutierrez, T. Kakuda, G. Picchio, G. De La Rosa, G. Beets, A. Vandevoorde, P. Van Remoortere, B. Jacquemyn, G. Quinn, D. Luo, S. Ouwerkerk-Mahadevan, L Vijgen, V. Van Eygen, M. Beumont
Journal: Journal of Hepatology (2015)
Aberrant Methylation of Multiple Tumor Suppressor genes and Expression Level of DNA Methyl Transferases(DNMT1, 3A, 3B) in Acute Myeloid Leukemia.
Authors: Cumhur Gokhan Ekmekci, Sema Sirma, Marina Gutierrez, Khalid Siraj, Duran Ustek, Kishor Bhatia, Ugur Ozbek
Journal: Blood (2004)
Statins for Primary Prevention
Authors: Rita F. Redberg, Mitchell H. Katz
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Eltrombopag Is Efficacious in Patients with Refractory Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Data from the EXTEND Study
Authors: Mansoor N Saleh, James B Bussel, Gregory Cheng, Balkis Meddeb, Paul M Burgess, Maria E De Obaldia, Nicole L Stone, Manuel Aivado
Journal: Blood (2008)
Usefulness of FDG-PET (Positron Emission Tomography) in the Discrimination between Hypoplastic Myelodysplastic Syndromes and Aplastic Anemia.
Authors: Masaaki Takatoku, Takahiro Nagashima, Toshihiko Sato, Tadashi Nagai, Norio Komatsu, Keiya Ozawa
Journal: Blood (2004)
Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.
Authors: Esther Natalie Oliva, Roberto Latagliata, Fortunato Morabito, Antonella Poloni, Riccardo Ghio, Agostino Cortelezzi, Carlo Finelli, Claudia Baratè, Francesca Ronco, Maria Antonietta Aloe Spiriti, Alessandra Ricco, Massimo Breccia, Caterina Alati, Giulia Praticò, Francesco Nobile
Journal: Blood (2009)
Analysis of T Cell Cloanlity of Ph+ Acute Lymphoblastic Leukemia with Chronic Gvhd in Continuous Remission after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Xiuli Wu, Qifa Liu, Yangqiu Li, Shaohua Chen, Xuan Du, Xianfeng Zha, Shuyun Zhou
Journal: Blood (2008)
Autologous Hematopoietic Stem Cell Collection and Transplantation in Acute Myeloid Leukemia Patients in Second Remission after Treatment with Fractionated Gentuzumab Ozogamycin.
Authors: Delphine Rea, Emmanuel Raffoux, Anne Laure Taksin, Adrienne De Labarthe, Nicolas Boissel, Jean Michel Miclea, Sylvie Castaigne, Herve Dombret
Journal: Blood (2006)
Inpatient Thrombophilia Workup in Patients with Acute Venous Thromboembolism
Authors: Vivek Rashmikant Mehta, Uzma Khan, Aparna Basu, Asif Jan, Bolanie Gbadamosi, Junad Chowdhury, Kamesh Parashar, Muznay Khawaja, Oluwatoyin Kufile, Rajiv Bhattarai, Sanya Thobani, Michael Korman
Journal: Blood (2015)
Treatment Outcome of Acute Myeloid Leukemia Patients From Brazil According to Karyotype, Presence or Not of FLT3-ITD and NPM1 Mutations, and BAALC Gene Expression.
Authors: Mariana Tereza Lira Benício, Ana Flávia Leonardi Tibúrcio Ribeiro, Ana Beatriz Firmato Glória, Antonio R Lucena-Araujo, Bárbara A Santana-Lemos, Rafael Jacomo, Juliana Godoy Assumpcao, Fabio Morato Oliveira, Sandra Guerra Xavier, Evandro Fagundes, Eduardo M. Rego
Journal: Blood (2010)
FRI0457 Recommendations for The Management of Comorbidities in Psoriatic Disease: Table 1
Authors: J.C. Torre-Alonso, L. Carmona, M. Moreno, E. Galíndez, J. Babío, P. Zarco, L.F. Linares, E. Collantes, M. Fernández-Barrial, J.C. Hermosa, P. Coto, C. Suárez, R. Almodόvar, J. Luelmo, V. Cárcaba, S. Castañeda, J. Gratacόs
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To establish recommendations for the management of comorbidities in patients with psoriatic disease (PsD). <h3>Methods</h3> A multidisciplinary panel drafted the recommendationsin a nominal group session. Evidence from four systematic reviews was added. Agreement was assessed by two-rounds Delphi technique. Recommendations with an agreement ≥7/10 by at least 70% of participants were kept in. <h3>Results</h3> A total of 19 recommendations on three key topics were issued: 1) screening of specific comorbidities, 2) specific preventive or therapeutic actions, and 3) general management. <h3>Conclusions</h3> Disease control coupled with the management of comorbidities is critical to ensure optimal patient care. These recommendations suggest actions on detection, management and integration of care in PsD. <h3>Acknowledgement</h3> GECOAP project was funded by Merck Sharp &amp; Dohme of Spain <h3>Disclosure of Interest</h3> None declared